About ATX
Amplia Therapeutics Limited (ATX) is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a role in chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Find out what a historical investment in Amplia Therapeutics would be worth today using our ATX stock calculator.
Market Capitalisation
$56.46M
Price-earnings ratio
-6.40
Dividend yield
-
High today
$0.11
Low today
$0.11
Open price
$0.11
52-week high
$0.28
52-week low
$0.10
Ready to start your investing journey with Stake?
Open an accountAnnouncements
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ATX
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in ATX on Stake
- Buy ATX from A$3 brokerage
- Invest in 2,500+ Aussie stocks and ETFs
- CHESS-sponsored ASX trades
Stock shown for demonstrative purposes only. A$3 brokerage up to A$30,000.
ATX related stocks